Recently Featured

Therapeutic mRNA Reverses Genetic Infertility in Male Mouse Model

March 24, 2026
According to a new Stem Cell Reports paper, scientists have demonstrated that targeted delivery of mRNA can restore sperm production and fertility in genetically infertile male mice without introducing permanent changes to the germline. Full details are provided in a paper titled “Messenger RNA delivery into Sertoli cells restores fertility to congenitally infertile male mice.”…

Roche Partner Zealand Posts Phase 2 Data for Amylin Obesity Drug

March 24, 2026
Zealand Pharma has released promising Phase 2 data for petrelintide, an amylin analog that was at the center of one of the largest obesity drug deals in recent history. The trial results indicate that patients experienced a mean weight reduction of up to 10.7%, showcasing the drug’s potential efficacy in addressing obesity, a growing public…

FDA Releases Activities Report on Generic Drug Program for FY 2025

March 24, 2026
The FDA has published its Activities Report for the Generic Drug Program for Fiscal Year 2025, as mandated by Section 807 of the FDA Reauthorization Act of 2017 (FDARA). This report provides a comprehensive overview of the agency’s performance in processing abbreviated new drug applications (ANDAs), which are crucial for the introduction of generic medications…

FDA Releases Activities Report on Generic Drug Program Under FDARA Title VIII

March 24, 2026
The FDA has published its latest Activities Report regarding the Generic Drug Program, as mandated by Section 807 of the FDA Reauthorization Act of 2017 (FDARA). This report provides essential insights into the status and performance of abbreviated new drug applications (ANDAs), reflecting the agency’s ongoing commitment to enhancing the efficiency and transparency of the…

Ongoing Cases